Molecule News and Research

RSS

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.

9 Apr 2013

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

9 Apr 2013

Study sheds light on role of retinoic acid in tissue development

In a ground-breaking study, researchers from the RIKEN Brain Science Institute in Japan report a new technique that allows them to visualize the distribution of retinoic acid in a live zebrafish embryo, in real-time.

9 Apr 2013

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream.

9 Apr 2013

Researchers discover that fruit fly mutation holds clues for treating motor neuron diseases

A team of researchers, led by Marc Freeman, PhD, an early career scientist with the Howard Hughes Medical Institute and associate professor of neurobiology at the University of Massachusetts Medical School have discovered a gene in the fruit fly Drosophila melanogaster that, when mutant, blocks the self-destruction of damaged axons, which could hold clues to treating motor neuron diseases, such as amyotrophic lateral sclerosis.

9 Apr 2013

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

A physician-researcher from The Children's Hospital of Philadelphia will lead the first-ever pediatric "Dream Team" solely focused on creating new treatments for the most challenging childhood cancers.

8 Apr 2013

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress, April 4-6, Monte Carlo, Monaco.

8 Apr 2013

National Jewish Health researchers unravel mystery of adjuvants

Aluminum salts, or alum, have been injected into billions of people as an adjuvant to make vaccines more effective.

8 Apr 2013

Vitamin D improves muscle function, boosts energy levels

Vitamin D is vital for making our muscles work efficiently and boosting energy levels, new research from Newcastle University has shown.

7 Apr 2013

Emergent BioSolutions provides update on TRU-016 Phase 1b study

Emergent BioSolutions Inc. today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia.

5 Apr 2013

Dermatology researcher secures federal grant to explore psoriasis

A dermatology researcher at Case Western Reserve University School of Medicine has secured a five-year, $1.9 million federal grant to explore whether a specific molecule may play a pivotal role in the development and progression of psoriasis.

5 Apr 2013

Research findings provide insight into severe bacterial infectious diseases

UT Southwestern Medical Center researchers report that a pathogen annually blamed for an estimated 90 million cases of food-borne illness defeats a host's immune response by using a fat-snipping enzyme to cut off cellular communication.

5 Apr 2013

AIM suppression could help prevent obesity-associated diseases

Obesity is linked to the widespread epidemics of diabetes and heart disease that plague society, but a lesser-known fact is that the weight can also lead to autoimmune disease.

5 Apr 2013

UC San Francisco researchers outline cell-based therapeutics as a "third pillar” of medicine

Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers.

4 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

Sanford-Burnham Medical Research Institute at Lake Nona announced the selection of the first five research organizations that will participate in the Florida Translational Research Program to advance drug discovery in the state.

3 Apr 2013

RUB biologists report that vitamin P ensures survival of motor neurons in culture

Biologists from the Ruhr-Universit-t Bochum have explored how to protect neurons that control movements from dying off.

3 Apr 2013

Molecule News and Research

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Study sheds light on role of retinoic acid in tissue development

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Researchers discover that fruit fly mutation holds clues for treating motor neuron diseases

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

National Jewish Health researchers unravel mystery of adjuvants

Vitamin D improves muscle function, boosts energy levels

Emergent BioSolutions provides update on TRU-016 Phase 1b study

Dermatology researcher secures federal grant to explore psoriasis

Research findings provide insight into severe bacterial infectious diseases

AIM suppression could help prevent obesity-associated diseases

UC San Francisco researchers outline cell-based therapeutics as a "third pillar” of medicine

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

RUB biologists report that vitamin P ensures survival of motor neurons in culture

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News